Enoximone (BioDeep_00000581662)

   


代谢物信息卡片


Enoximone

化学式: C12H12N2O2S (248.0619452)
中文名称: 依诺昔酮
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1=C(NC(=O)N1)C(=O)C2=CC=C(C=C2)SC
InChI: InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16)

描述信息

C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CE - Phosphodiesterase inhibitors
D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058987 - Phosphodiesterase 3 Inhibitors
D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
D020011 - Protective Agents > D002316 - Cardiotonic Agents

同义名列表

1 个代谢物同义名

Enoximone



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Jan Beute, Alex KleinJan. Phosphodiesterase-3 Inhibitor Enoximone in SARS-CoV-2 Infection. Journal of aerosol medicine and pulmonary drug delivery. 2021 09; 34(5):322-323. doi: 10.1089/jamp.2021.0042. [PMID: 34495768]
  • Baldassare Ferro, Roberta Cinelli, Lara Vegnuti, Anna Maria Piras, Paolo Roncucci. The Potential Role of Aerosolized Phosphodiesterase 3 Inhibitor Enoximone in the Management of Coronavirus Disease 2019 Hypoxemia: A Case Report. Journal of aerosol medicine and pulmonary drug delivery. 2021 08; 34(4):262-264. doi: 10.1089/jamp.2021.0024. [PMID: 34152840]
  • Jan Beute, Pieter Boermans, Bart Benraad, Jan Telman, Zuzana Diamant, Alex KleinJan. PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia. Experimental lung research. 2021 04; 47(3):149-160. doi: 10.1080/01902148.2021.1881189. [PMID: 33544007]
  • Emiliano Angeloni, Giovanni Melina, Antonino Roscitano, Simone Refice, Fabio Capuano, Cosimo Comito, Umberto Benedetto, Riccardo Sinatra. Perioperative administration of enoximone and renal function after cardiac surgery: a propensity-matched analysis. International journal of cardiology. 2013 Sep; 167(5):1961-6. doi: 10.1016/j.ijcard.2012.05.021. [PMID: 22633430]
  • Koen J Hartemink, A B Johan Groeneveld. Vasopressors and inotropes in the treatment of human septic shock: effect on innate immunity?. Inflammation. 2012 Feb; 35(1):206-13. doi: 10.1007/s10753-011-9306-8. [PMID: 21347606]
  • Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
  • S Suttner, J Boldt, A Mengistu, K Lang, J Mayer. Influence of continuous perioperative beta-blockade in combination with phosphodiesterase inhibition on haemodynamics and myocardial ischaemia in high-risk vascular surgery patients. British journal of anaesthesia. 2009 May; 102(5):597-607. doi: 10.1093/bja/aep062. [PMID: 19336536]
  • Arzu Pampal, I Onur Ozen, Billur Demirogullari, I Hakki Gol, M Meral Guclu, Neslihan Bukan, Aylar Poyraz, Ramazan Karabulut, A Can Basaklar, Nuri Kale. Apart from the other members of PDE inhibitors' family, enoximone does not enhance renal ischemic reperfusion injury: the effects of enoximone on renal ischemia reperfusion. Renal failure. 2009; 31(10):971-6. doi: 10.3109/08860220903216873. [PMID: 20030534]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • S Suttner, J Boldt, K Lang, J Mayer, K Röhm, S N Piper. [Continuous beta-block with esmolol in combination with enoximone: influence on cardiac function in high risk patients undergoing vascular surgery]. Der Anaesthesist. 2008 Mar; 57(3):231-41. doi: 10.1007/s00101-008-1313-2. [PMID: 18270676]
  • Matthias Heringlake, Marit Wernerus, Julia Grünefeld, Stephan Klaus, Hermann Heinze, Matthias Bechtel, Ludger Bahlmann, Jochen Poeling, Julika Schön. The metabolic and renal effects of adrenaline and milrinone in patients with myocardial dysfunction after coronary artery bypass grafting. Critical care (London, England). 2007; 11(2):R51. doi: 10.1186/cc5904. [PMID: 17470271]
  • Jan-Peter Braun, Dominik Jasulaitis, Maryam Moshirzadeh, Ulrich R Doepfmer, Marc Kastrup, Christian von Heymann, Pascal M Dohmen, Wolfgang Konertz, Claudia Spies. Levosimendan may improve survival in patients requiring mechanical assist devices for post-cardiotomy heart failure. Critical care (London, England). 2006 Feb; 10(1):R17. doi: 10.1186/cc3979. [PMID: 16420666]
  • Sascha Meyer, Sven Gottschling, Ali Baghai, Donald Wurm, Ludwig Gortner. Arginine-vasopressin in catecholamine-refractory septic versus non-septic shock in extremely low birth weight infants with acute renal injury. Critical care (London, England). 2006; 10(3):R71. doi: 10.1186/cc4917. [PMID: 16677425]
  • W H Wilson Tang, Gary S Francis. The year in heart failure. Journal of the American College of Cardiology. 2005 Dec; 46(11):2125-33. doi: 10.1016/j.jacc.2005.10.018. [PMID: 16325052]
  • Ortrud Vargas Hein, Klaudia Misterek, Jan-Peer Tessmann, Vera van Dossow, Michael Krimphove, Claudia Spies. Time course of endothelial damage in septic shock: prediction of outcome. Critical care (London, England). 2005 Aug; 9(4):R323-30. doi: 10.1186/cc3532. [PMID: 16137344]
  • Krishna Lalukota, John G F Cleland, Lee Ingle, Andrew L Clark, Alison P Coletta. Clinical trials update from the Heart Failure Society of America: EMOTE, HERB-CHF, BEST genetic sub-study and RHYTHM-ICD. European journal of heart failure. 2004 Dec; 6(7):953-5. doi: 10.1016/j.ejheart.2004.10.003. [PMID: 15556058]
  • Joachim Boldt, Christian Brosch, Andreas Lehmann, Stephan Suttner, Frank Isgro. The prophylactic use of the beta-blocker esmolol in combination with phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients. Anesthesia and analgesia. 2004 Oct; 99(4):1009-1017. doi: 10.1213/01.ane.0000132969.88550.96. [PMID: 15385341]
  • Hannelore I G Ringe, Verena Varnholt, Gerhard Gaedicke. Cardiac rescue with enoximone in volume and catecholamine refractory septic shock. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2003 Oct; 4(4):471-5. doi: 10.1097/01.pcc.0000074275.61913.72. [PMID: 14525645]
  • Günter Görge, Stephan Flüchter, Michael Kirstein, Thomas Kunz. [Sex, erectile dysfunction, and the heart: a growing problem]. Herz. 2003 Jun; 28(4):284-90. doi: 10.1007/s00059-003-2478-8. [PMID: 12825143]
  • Joachim Boldt, Christian Brosch, Stefan Suttner, Sven N Piper, Andreas Lehmann, Christiane Werling. Prophylactic use of the phospodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function. Intensive care medicine. 2002 Oct; 28(10):1462-9. doi: 10.1007/s00134-002-1435-y. [PMID: 12373472]
  • H Kern, T Schröder, M Kaulfuss, M Martin, W J Kox, C D Spies. Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients. Critical care medicine. 2001 Aug; 29(8):1519-25. doi: 10.1097/00003246-200108000-00004. [PMID: 11505119]
  • P D Booker, S Gibbons, J I Stewart, A Selby, E Wilson-Smith, M Pozzi. Enoximone pharmacokinetics in infants. British journal of anaesthesia. 2000 Aug; 85(2):205-10. doi: 10.1093/bja/85.2.205. [PMID: 10992825]
  • J L Cracowski, F Stanke-Labesque, O Chavanon, D Blin, J M Mallion, G Bessard, P Devillier. Vasorelaxant actions of enoximone, dobutamine, and the combination on human arterial coronary bypass grafts. Journal of cardiovascular pharmacology. 1999 Nov; 34(5):741-8. doi: 10.1097/00005344-199911000-00017. [PMID: 10547092]
  • O Schulz, V Mitrovic, M Schönburg, J Thormann. High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements?. American heart journal. 1999 May; 137(5):887-94. doi: 10.1016/s0002-8703(99)70413-8. [PMID: 10220638]
  • C F Wippermann, F X Schmid, B Eberle, R G Huth, C Kampmann, D Schranz, H Oelert. Reduced inotropic support after aprotinin therapy during pediatric cardiac operations. The Annals of thoracic surgery. 1999 Jan; 67(1):173-6. doi: 10.1016/s0003-4975(98)00974-6. [PMID: 10086544]
  • J Boldt, G Rothe, E Schindler, C Döll, G Görlach, G Hempelmann. Can clonidine, enoximone, and enalaprilat help to protect the myocardium against ischaemia in cardiac surgery?. Heart (British Cardiac Society). 1996 Sep; 76(3):207-13. doi: 10.1136/hrt.76.3.207. [PMID: 8868976]
  • S Berti, C Palmieri, M Ravani, R Bonini, M R Iascone, A Clerico, C Manfredi, G Iervasi, P Ferrazzi, A Biagini. Acute enoximone effect on systemic and renal hemodynamics in patients with heart failure. Cardiovascular drugs and therapy. 1996 Mar; 10(1):81-7. doi: 10.1007/bf00051134. [PMID: 8723174]
  • S Morita, Y Sawai, J F Heeg, Y Koike. Pharmacokinetics of enoximone after various intravenous administrations to healthy volunteers. Journal of pharmaceutical sciences. 1995 Feb; 84(2):152-7. doi: 10.1002/jps.2600840206. [PMID: 7738792]
  • J Youssef, S Abdel-aleem, M Badr. Enoximone inhibits hepatic mitochondrial long-chain acyl-CoA synthetase. Toxicology letters. 1994 Oct; 74(1):15-21. doi: 10.1016/0378-4274(94)90070-1. [PMID: 8085267]
  • A Goullon, D Ries. Experience with the Berlin Heart Assist Device. Artificial organs. 1994 Jul; 18(7):490-3. doi: 10.1111/j.1525-1594.1994.tb03365.x. [PMID: 7980091]
  • D Trenk, E Jähnchen. [Clinico-pharmacologic aspects of therapy with enoximone]. Zeitschrift fur Kardiologie. 1994; 83 Suppl 2(?):7-14. doi: NULL. [PMID: 8091828]
  • V Mitrovic, J Neuzner, H Opper, J Thormann, M Schlepper. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine]. Zeitschrift fur Kardiologie. 1994; 83 Suppl 2(?):37-48. doi: NULL. [PMID: 8091823]
  • J W Park, R Heinzler, J H Wirtz, M Fieten-Rumswinkel, P Braun, E May, R Hetzer, K W Heinrich. Low-dose enoximone therapy in pre-transplant patients: hemodynamic, echocardiographic, and neurohumoral findings. Zeitschrift fur Kardiologie. 1994; 83 Suppl 2(?):49-53. doi: NULL. [PMID: 8091824]
  • J W Park, J H Wirtz, E May, S Mertens, P Braun, R Heinzler, R Hetzer, C S Kang, K W Heinrich. Enoximone therapy as pharmacological bridging to cardiac transplantation. Yonsei medical journal. 1993 Mar; 34(1):63-70. doi: 10.3349/ymj.1993.34.1.63. [PMID: 8379184]
  • H Masuoka, M Ito, M Sugioka, H Kozeki, T Konishi, T Tanaka, T Nakano. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent. Biochemical and biophysical research communications. 1993 Jan; 190(2):412-7. doi: 10.1006/bbrc.1993.1063. [PMID: 8381275]
  • M Sold, W Engelhardt, E Hartung, H Trautner. [Suppression of the adrenal cortex by enoximone. A proband study with documentation of the hemodynamic course]. Der Anaesthesist. 1992 Nov; 41(11):680-4. doi: . [PMID: 1463155]
  • J G Preuner, R Gieseke, W Kasper, D Birnbaum. Influence of ischaemic cardioplegic arrest on the haemodynamic efficacy of the PDE-III inhibitor, enoximone. European heart journal. 1991 Dec; 12 Suppl F(?):153-6. doi: 10.1093/eurheartj/12.suppl_f.153. [PMID: 1839531]
  • A M Burns, G R Park. Prolonged action of enoximone in renal failure. Anaesthesia. 1991 Oct; 46(10):864-5. doi: 10.1111/j.1365-2044.1991.tb09604.x. [PMID: 1835317]
  • N A Smith, R E Kates, C Lebsack, M A Ruder, R H Mead, T Bekele, R A Okerholm, G M Rubin, R A Winkle. Clinical pharmacology of intravenous enoximone: pharmacodynamics and pharmacokinetics in patients with heart failure. American heart journal. 1991 Sep; 122(3 Pt 1):755-63. doi: 10.1016/0002-8703(91)90522-j. [PMID: 1831585]
  • M A Ruder, C Lebsack, R A Winkle, R H Mead, N Smith, R E Kates. Disposition kinetics of orally administered enoximone in patients with moderate to severe heart failure. Journal of clinical pharmacology. 1991 Aug; 31(8):702-8. doi: 10.1002/j.1552-4604.1991.tb03763.x. [PMID: 1831816]
  • V Mitrovic, O Petrovic, H Bahavar, J Neuzner, H A Dieterich, M Schlepper. Antiischemic and hemodynamic effects of an oral single dose of 150 mg of the phosphodiesterase inhibitor enoximone in patients with coronary artery disease--relation to plasma concentration. Cardiovascular drugs and therapy. 1991 Aug; 5(4):689-95. doi: 10.1007/bf03029742. [PMID: 1832289]
  • S R Holmberg, A J Williams. Phosphodiesterase inhibitors and the cardiac sarcoplasmic reticulum calcium release channel: differential effects of milrinone and enoximone. Cardiovascular research. 1991 Jul; 25(7):537-45. doi: 10.1093/cvr/25.7.537. [PMID: 1655266]
  • E Jähnchen, D Trenk. [Pharmacology and pharmacokinetics of enoximone]. Zeitschrift fur Kardiologie. 1991; 80 Suppl 4(?):21-6. doi: NULL. [PMID: 1833893]
  • H J Gilfrich, H A Dieterich. [Tolerance of enoximone in patients with heart failure]. Zeitschrift fur Kardiologie. 1991; 80 Suppl 4(?):93-7. doi: NULL. [PMID: 1833904]
  • K Breithaupt, G G Belz, S Kempinski, K H Schicketanz, H A Dieterich. [Effect of oral administration of enoximone on cardiac performance, arterial circulation at rest and on the vasoconstrictor effect of local noradrenaline infusions into the human hand vein]. Zeitschrift fur Kardiologie. 1991; 80 Suppl 4(?):15-20. doi: NULL. [PMID: 1833892]
  • D E Birnbaum, J G Preuner, R Gieseke, W Kasper-König, D Trenk, E Jähnchen, H A Dieterich. [Comparison of the hemodynamic effect of enoximone and dopamine in patients after coronary bypass operation]. Zeitschrift fur Kardiologie. 1991; 80 Suppl 4(?):47-52. doi: NULL. [PMID: 1833897]
  • H E Zeplin. [The effect of enoximone and catecholamines on renal function after open heart surgery]. Zeitschrift fur Kardiologie. 1991; 80 Suppl 4(?):59-62. doi: NULL. [PMID: 1833899]
  • K Breithaupt, G G Belz, S Kempinski, K H Schicketanz, H A Dieterich. The effects of oral enoximone on cardiac performance, calf arterial blood flow, and constrictor effects of norepinephrine infused into hand veins in humans. Journal of cardiovascular pharmacology. 1990 Sep; 16(3):349-53. doi: 10.1097/00005344-199009000-00001. [PMID: 1700203]
  • P Gibelin, R Garraffo, V Sbirrazzuoli, P Lapalus, P Morand. [Treatment of chronic cardiac insufficiency with intravenous bolus enoximone. Study of a pharmacokinetic-hemodynamic relation]. Archives des maladies du coeur et des vaisseaux. 1990 Sep; 83 Spec No 3(?):75-81. doi: NULL. [PMID: 2147839]
  • R A Winkle, N A Smith, M A Ruder, R H Mead, C Lebsack, T Bekele, R E Kates, J Rubin, R Okerholm. Pharmacodynamics of enoximone during intravenous infusion. International journal of cardiology. 1990 Jul; 28 Suppl 1(?):S1-2. doi: 10.1016/0167-5273(90)90142-r. [PMID: 2145232]
  • D Loisance, P Deleuze, M L Hillion, J L Dubois-Rande, J P Saal, C Benvenuti, N Shiiya, F Wan. The real impact of mechanical bridge strategy in patients with severe acute infarction. ASAIO transactions. 1990 Jul; 36(3):M135-7. doi: NULL. [PMID: 2147554]
  • D Trenk, F Hertrich, B Winkelmann, T Glauner, H A Dieterich, E Jähnchen. Lack of effect of enoximone on the pharmacokinetics of digoxin in patients with congestive heart failure. Journal of clinical pharmacology. 1990 Mar; 30(3):235-40. doi: 10.1002/j.1552-4604.1990.tb03467.x. [PMID: 2138170]
  • H Masuoka, M Ito, T Nakano, M Naka, T Tanaka. Effects of amrinone and enoximone on the subclasses of cyclic AMP phosphodiesterase from human heart and kidney. Journal of cardiovascular pharmacology. 1990 Feb; 15(2):302-7. doi: 10.1097/00005344-199002000-00018. [PMID: 1689427]
  • E Tarral, F Jehl, C Gallion, H Monteil. [Determination of enoximone and its principle metabolite in serum and urine using high pressure liquid chromatography]. Therapie. 1990 Jan; 45(1):1-6. doi: NULL. [PMID: 2140472]
  • J Boldt, H A Adams, B Zickmann, D Kling, G Hempelmann. Comparative effects of enoximone and theophylline on plasma catecholamines and haemodynamics in cardiosurgical patients. European journal of clinical pharmacology. 1990; 38(5):431-6. doi: 10.1007/bf02336679. [PMID: 2143137]
  • J Boldt, D Kling, H A Dietevich, G Hempelmann. Drug interactions: the new phosphodiesterase inhibitor enoximone and the calcium channel blocker nifedipine in coronary surgery patients--influence on hemodynamics and plasma concentrations. Journal of cardiovascular pharmacology. 1990 Jan; 15(1):37-43. doi: NULL. [PMID: 1688980]
  • J Boldt, D Kling, H A Dieterich, P Marck, G Hempelmann. The new phosphodiesterase inhibitor enoximone in patients following cardiac surgery--pharmacokinetics and influence on parameters of coagulation. Intensive care medicine. 1990; 16(1):54-9. doi: 10.1007/bf01706326. [PMID: 2138182]
  • J L Vincent, M Léon, J Berré. The role of enoximone in the treatment of cardiogenic shock. Cardiology. 1990; 77 Suppl 3(?):21-6; discussion 27. doi: 10.1159/000174667. [PMID: 2176130]
  • R C Dage, R A Okerholm. Pharmacology and pharmacokinetics of enoximone. Cardiology. 1990; 77 Suppl 3(?):2-13; discussion 27. doi: 10.1159/000174664. [PMID: 2148277]
  • D E Birnbaum, J G Preuner, R Gieseke, D Trenk, E Jaehnchen. Enoximone versus dopamine in patients being weaned from cardiopulmonary bypass. Cardiology. 1990; 77 Suppl 3(?):34-41; discussion 62. doi: 10.1159/000174669. [PMID: 2148278]
  • P Fiegel, D Trenk, E Jaehnchen, H A Dieterich. Pharmacokinetics of intravenous enoximone in dialysis patients. Journal of cardiovascular pharmacology. 1989; 14 Suppl 1(?):S20-3. doi: NULL. [PMID: 2480480]
  • G Clifton, G McMahon, J Ryan, R Vargas, T Bekele, D Wallin. The effects of enoximone on renal function in patients with congestive heart failure. Clinical pharmacology and therapeutics. 1989 Jan; 45(1):85-91. doi: 10.1038/clpt.1989.13. [PMID: 2521320]
  • V Mitrovic, J Neuzner, H Husseini, M Volz, M Schlepper. The influence of various degrees of cardiac failure, chronic medical treatment, and acute additional enoximone application on the parameters of the vasopressor system. Journal of cardiovascular pharmacology. 1989; 14 Suppl 1(?):S40-9. doi: NULL. [PMID: 2480485]
  • V Mitrovic, J Thormann, J Neuzner, H Bahawar, M Volz, H A Dieterich, M Schlepper. Hemodynamic, antiischemic, and neurohumoral effects of enoximone in patients with coronary artery disease. American heart journal. 1989 Jan; 117(1):106-11. doi: 10.1016/0002-8703(89)90663-7. [PMID: 2563185]
  • R H Hook, H Boxenbaum, G A Thompson, R A Okerholm. Human serum and plasma protein binding of enoximone and its sulfoxide metabolite. Journal of pharmaceutical sciences. 1988 Dec; 77(12):1012-7. doi: 10.1002/jps.2600771205. [PMID: 3244103]
  • J L Vincent, E Carlier, J Berré, C W Armistead, R J Kahn, E Coussaert, F Cantraine. Administration of enoximone in cardiogenic shock. The American journal of cardiology. 1988 Sep; 62(7):419-23. doi: 10.1016/0002-9149(88)90970-8. [PMID: 2970777]
  • G G Belz, T Meinicke, M Schäfer-Korting. The relationship between pharmacokinetics and pharmacodynamics of enoximone in healthy man. European journal of clinical pharmacology. 1988; 35(6):631-5. doi: 10.1007/bf00637599. [PMID: 2976670]
  • J J Lima, C V Leier, L Holtz, J Sterechele, B J Shields, J J MacKichan. Oral enoximone pharmacokinetics in patients with congestive heart failure. Journal of clinical pharmacology. 1987 Sep; 27(9):654-60. doi: 10.1002/j.1552-4604.1987.tb03083.x. [PMID: 2960700]
  • R A Okerholm, K Y Chan, J F Lang, G A Thompson, S J Ruberg. Biotransformation and pharmacokinetic overview of enoximone and its sulfoxide metabolite. The American journal of cardiology. 1987 Aug; 60(5):21C-26C. doi: 10.1016/0002-9149(87)90520-0. [PMID: 2956863]
  • T Pop, N Treese, G M Cremer, K D Haegele, J Meyer. Electrophysiological effects of intravenous MDL 17.043. International journal of cardiology. 1986 Aug; 12(2):223-32. doi: 10.1016/0167-5273(86)90245-7. [PMID: 2943683]
  • J D Cooper, D C Turnell. Automatic preparation of human serum samples for analysis of the drug enoximone and its sulphoxide metabolite using high-performance liquid chromatography. Journal of chromatography. 1986 Jul; 380(1):109-16. doi: 10.1016/s0378-4347(00)83629-4. [PMID: 2943750]
  • B F Uretsky, T Generalovich, J G Verbalis, A M Valdes, P S Reddy. Comparative hemodynamic and hormonal response of enoximone and dobutamine in severe congestive heart failure. The American journal of cardiology. 1986 Jul; 58(1):110-6. doi: 10.1016/0002-9149(86)90252-3. [PMID: 2942027]
  • B F Uretsky, A M Valdes, P S Reddy. Positive inotropic therapy for short-term support and long-term management of patients with congestive heart failure: hemodynamic effects and clinical efficacy of MDL 17,043. Circulation. 1986 Mar; 73(3 Pt 2):III219-29. doi: NULL. [PMID: 2935328]
  • B F Uretsky, T Generalovich, J G Verbalis, A M Valdes, P S Reddy. MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. Journal of the American College of Cardiology. 1985 Jun; 5(6):1414-21. doi: 10.1016/s0735-1097(85)80358-2. [PMID: 3158689]
  • B F Uretsky, J G Verbalis, T Generalovich, A Valdes, P S Reddy. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. The American journal of physiology. 1985 Mar; 248(3 Pt 2):H396-402. doi: 10.1152/ajpheart.1985.248.3.h396. [PMID: 3156513]
  • D el Allaf, V D'Orio, J Carlier. The new inotropic phosphodiesterase inhibitors. Archives internationales de physiologie et de biochimie. 1984 Nov; 92(4):S69-79. doi: 10.3109/13813458409071165. [PMID: 6085243]
  • R G Alken, G G Belz, K D Haegele, T Meinicke, P J Schechter. Kinetics of fenoximone, a new cardiotonic, in healthy subjects. Clinical pharmacology and therapeutics. 1984 Aug; 36(2):209-16. doi: 10.1038/clpt.1984.164. [PMID: 6235081]
  • K Y Chan, D F Ohlweiler, J F Lang, R A Okerholm. Simultaneous analysis of a new cardiotonic agent, MDL 17,043, and its major sulfoxide metabolite in plasma by high-performance liquid chromatography. Journal of chromatography. 1984 Mar; 306(?):249-56. doi: 10.1016/s0378-4347(00)80887-7. [PMID: 6232282]
  • R Arbogast, C Brandt, K D Haegele, J L Fincker, P J Schechter. Hemodynamic effects of MDL 17,043, a new cardiotonic agent, in patients with congestive heart failure: comparison with sodium nitroprusside. Journal of cardiovascular pharmacology. 1983 Nov; 5(6):998-1004. doi: 10.1097/00005344-198311000-00013. [PMID: 6196573]
  • K Y Chan, J F Lang, R A Okerholm. Quantitative determination of cardiotonic agent MDL 17,043 in plasma by reversed-phase high-performance liquid chromatography. Journal of chromatography. 1983 Feb; 272(2):396-400. doi: 10.1016/s0378-4347(00)86146-0. [PMID: 6220024]